Phase II single-arm study of palbociclib and cetuximab in anti-EGFR naïve patients with KRAS/NRAS/BRAF wild-type, metastatic colorectal cancer.

Oncologist · 2025 · PMC12526856 · PMID 40990835

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significanceno p-value reported

12 In our study, there was no significant ( P = .07) association between decreased TK activity and improved PFS, however, further studies could be conducted to better define the borderline significance.

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.